Case Series

Published: Oct 12, 2025 | DOI: 10.24911/ejmcr.9-2271

The un-ending saga of Seronegative autoimmune encephalitis


Authors: Deepinder Kaur Maini orcid logo , Ankita Kumari , Rajiv Anand , Saurabh Arora , Atul Prasad , Nishant Tomar , Anubhav Gupta , Tanzeel Ahmad Wani


Article Info

Authors

Deepinder Kaur Maini

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

orcid logo ORCID

Ankita Kumari

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Rajiv Anand

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Saurabh Arora

Department of Nuclear Medicine, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Atul Prasad

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Nishant Tomar

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Anubhav Gupta

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Tanzeel Ahmad Wani

Department of Neurology, Dr. B.L. Kapur Memorial Hospital, New Delhi, India

Publication History

Received: June 27, 2025

Accepted: August 14, 2025

Published: October 12, 2025


Abstract


Objective: To characterize the clinical presentation, diagnostic challenges, neuroimaging findings, and treatment response in patients with seronegative autoimmune encephalitis (AIE) presenting as new-onset refractory status epilepticus (NORSE) and to assess the utility of fluorodeoxyglucose positron emission tomography (FDG-PET) and electroencephalogram (EEG) in diagnosis
and disease monitoring.
Background: NORSE is a life-threatening condition that often arises in the setting of AIE. While seropositive AIE has established diagnostic criteria, seronegative AIE remains a diagnostic challenge due to the absence of autoantibodies and non-specific findings on conventional investigations.
Methods: This is a prospective case series of four patients with seronegative AIE presenting as NORSE. Clinical history, cerebrospinal fluid (CSF) findings, magnetic resonance imaging (MRI), EEG, and FDG-PET results were analyzed. Immunotherapeutic interventions included intravenous immunoglobulin, corticosteroids, plasma exchange, rituximab, and tocilizumab.
Results: We present four patients with NORSE, characterized by challenging diagnoses due to negative antibodies in serological and CSF analyses. All patients exhibited normal MRI brain results. FDG PET revealed patterns of hypermetabolism or hypometabolism in sequential imaging. Therefore, indicating the potential function of FDG PET as an imaging biomarker in seronegative AIE.
Conclusion: Seronegative AIE presenting as NORSE remains a diagnostic and therapeutic challenge. Conventional MRI and CSF studies may be inconclusive, whereas FDG-PET and EEG provide valuable insights into disease activity. Early and aggressive immunotherapy can improve seizure control and clinical outcomes. Further research is needed to refine diagnostic criteria and treatment strategies for seronegative AIE.


Keywords: Autoimmune encephalitis (AIE), Status Epilepticus, New onset refractory status epilepticus (NORSE), neuroradiology